期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 85, 期 2, 页码 217-221出版社
WILEY
DOI: 10.1038/clpt.2008.200
关键词
-
It is estimated that the development of a new anticancer agent costs US$800 million to 1 billion and takes more than a decade between conception and approval.(1) However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models.(2) This raises serious concerns as to whether such models are predictive of drug efficacy in humans, particularly in the current era of new targeted therapies, and supports the development of alternative approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据